As the US opioid addiction crisis continues, it seems the FDA is less than convinced about the new painkilling drugs that the pharma industry is developing.
Sandoz has signed a potential $293 million agreement to develop and market Durect’s Posimir, an extended-release, locally-acting, non-opioid painkiller in the US.
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.